Personal import allowances, compared
What I would check first on personal import allowances is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
On the opening post — agreed on the reasoning, with one qualification.
Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.
Worth separating two things that post #4 runs together.
On personal import allowances, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Read the full topic (10 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Cross-border purchase within the EU: the actual rules
Posting this under the heading it deserves: Second pass at: Cross-border purchase within the EU: the actual rules Everything below is what sits behind that. The question about Cross-border purchase within…
|
+135 | 139 | 8.7k | 16mo |
|
Revisiting: Language barriers in accessing a prescription abroad
Posting this under the heading it deserves: Revisiting: Language barriers in accessing a prescription abroad Everything below is what sits behind that. Asking about Language barriers in accessing on behalf of…
|
+131 | 148 | 28k | 5mo |
|
About the International category
Country-by-country availability and legality, dated because it changes constantly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+6 | 11 | 240 | 22mo |
|
Language barriers in accessing a prescription abroad
Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about language barriers in accessing in a thread last spring…
|
2 | 22k | 1h | |
|
What changed in 2026, by region
What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…
|
+110 | 122 | 1.4k | 18mo |
Related topics — sharing the tags EMA, MHRA, telehealth
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. Cross-border purchase rules within — I have the observation and I do not trust my…
|
+12 | 16 | 2.8k | 11mo |
|
Second pass at: When your prescriber and the evidence disagree
Second pass at: When your prescriber and the evidence disagree — setting out what I have, and where I think it stops being reliable. What changes if the standard account of prescriber is wrong? I ask because…
|
+51 | 55 | 9.2k | 2d |
|
MHRA statements, read directly
MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each…
|
+93 | 101 | 2.2k | 5mo |
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. Asking what a regulator's document actually…
|
2 | 5k | 11mo | |
|
Discussing something you have already been doing — the long version
Discussing something you have already been doing — the long version Writing it up because I had to work it out twice and would rather nobody else did. A question about how to describe something to a clinician…
|
+14 | 18 | 58k | 12mo |